المؤلفون: Edsjö, Anders, Russnes, Hege G., Lehtiö, Janne, Tamborero, David, Hovig, Eivind, Stenzinger, Albrecht, Rosenquist, Richard, Janowska, Agnieszka, Rioja, Alba L. pez, Razzak, Ali, Lepland, Anni, Marra, Antonio, Planken, Anu, Helland, Åslaug, Patocs, Attila, Mainoli, Beatrice, Ryll, Bettina, Brasiuniene, Birute, Kazdal, Daniel, Cerina, Dora, Hult, Ebba Hallersjö, Baltruškevičienė, Edita, Vrdoljak, Eduard, Chavarria, Elena, Garralda, Elena, Aas, Eline, Bjørgo, Elisa, Voest, Emile, Curigliano, Giuseppe, Fagereng, Gro Live, Gelderblom, Hans, Verheul, Henk, Timmer, Hans, Brana, Irene, Lugowska, Iwona, Blay, Jean-Yves, Oliveira, Julio, Rekker, Kadri, Toome, Kadri, Jalkanen, Katriina, Taskén, Kjetil, Smeland, Knut, Ojamaa, Kristiina, Rohrberg, Kristoffer Staal, Verlingue, Loic, Antouly, Manon, Mustonen, Mika, Zagami, Paola, Nagy, P. ter, Nygren, Peter, Asplund, Peter, Sabaliauskaite, Rasa, Henrique, Rui, van Waalwijk van Doorn-Khosrovani, Sahar Barjesteh, Brabrand, Sigmund, Ekman, Simon, Mohammad, Soemeya Haj, Jarmalaite, Sonata, Juslin, Tanja, Kahre, Tiina, Kringelbach, Tina, Guren, Tormod, Lassen, Ulrik, Grolmusz, Vince Kornél, Alberu, Xenia Villabour

المصدر: Edsjö , A , Russnes , H G , Lehtiö , J , Tamborero , D , Hovig , E , Stenzinger , A , Rosenquist , R , Janowska , A , Rioja , A L P , Stenzinger , A , Razzak , A , Edsjö , A , Lepland , A , Marra , A , Planken , A , Helland , Å , Patocs , A , Mainoli , B , Ryll , B , Brasiuniene , B , Kazdal , D , Tamborero , D , Cerina , D , Hult , E H ....

العلاقة: https://research.vumc.nl/en/publications/f9b64ff1-0d53-45ca-9a32-a3a99b455d6cTest

الإتاحة: https://doi.org/10.1111/joim.13785Test
https://research.vumc.nl/en/publications/f9b64ff1-0d53-45ca-9a32-a3a99b455d6cTest
http://www.scopus.com/inward/record.url?scp=85192176648&partnerID=8YFLogxKTest

المؤلفون: Huhtaniemi, Riikka, Sipila, Petra, Junnila, Arttu, Oksala, Riikka, Knuuttila, Matias, Mehmood, Arfa, Aho, Eija, Laajala, Teemu D., Aittokallio, Tero, Laiho, Asta, Elo, Laura, Ohlsson, Claes, Thulin, Malin Hagberg, Kallio, Pekka, Makela, Sari, Mustonen, Mika V. J., Poutanen, Matti

المساهمون: Institute for Molecular Medicine Finland, Medicum, University of Helsinki, Helsinki Institute for Information Technology, Tero Aittokallio / Principal Investigator, Bioinformatics, Department of Mathematics and Statistics

مصطلحات موضوعية: ANDROGEN RECEPTOR EXPRESSION, GENE-EXPRESSION, MOLECULAR CHARACTERIZATION, LINEAGE PLASTICITY, DRUG-INTERACTION, ENZALUTAMIDE, THERAPY, AMPLIFICATION, ABIRATERONE, GUIDELINES, Cancers

وصف الملف: application/pdf

العلاقة: The Academy of Finland, Cancer Society of Finland, Drug Research Doctoral Programme, Finnish Cultural Foundation, Orion Pharma, Sigrid Juselius Foundation, Swedish government, under the Agreement for Medical Education and Research, and the Swedish Research Council and University of Turku.; Huhtaniemi , R , Sipila , P , Junnila , A , Oksala , R , Knuuttila , M , Mehmood , A , Aho , E , Laajala , T D , Aittokallio , T , Laiho , A , Elo , L , Ohlsson , C , Thulin , M H , Kallio , P , Makela , S , Mustonen , M V J & Poutanen , M 2022 , ' High intratumoral dihydrotestosterone is associated with antiandrogen resistance in VCaP prostate cancer xenografts in castrated mice ' , iScience , vol. 25 , no. 5 , 104287 . https://doi.org/10.1016/j.isci.2022.104287Test; ORCID: /0000-0002-0886-9769/work/121253192; http://hdl.handle.net/10138/350071Test; c50eef8d-2912-4621-b170-9e653746430d; 000859524200002

الإتاحة: http://hdl.handle.net/10138/350071Test

المؤلفون: Reza Felix, Mariana, Jones, Robert, Aspegren, John, Massard, Christophe, Mattila, Leena, Mustonen, Mika, Wollmer, Per, Trägårdh, Elin, Bondesson, Eva, Edenbrandt, Lars, Fizazi, Karim, Bjartell, Anders

المصدر: European Urology Focus BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation EpiHealth: Epidemiology for Health. 2(5):547-552

مصطلحات موضوعية: Androgen receptor antagonists, Bone metastasis, Bone scan index, Metastatic castration-resistant prostate cancer, ODM-201, Radiographic progression-free survival, Medicin och hälsovetenskap, Klinisk medicin, Cancer och onkologi, Medical and Health Sciences, Clinical Medicine, Cancer and Oncology, Urologi och njurmedicin, Urology and Nephrology

الوصول الحر: https://lup.lub.lu.se/record/04482c4d-1561-4232-a5c8-fb543115ac30Test
http://dx.doi.org/10.1016/j.euf.2016.01.005Test

المؤلفون: Bono, Petri, Massard, Christophe, Peltola, Katriina J., Azaro, Analia, Italiano, Antoine, Kristeleit, Rebecca S., Curigliano, Giuseppe, Lassen, Ulrik, Arkenau, Hendrik-Tobias, Hakulinen, Pasi, Garratt, Chris, Ikonen, Tarja, Mustonen, Mika V. J., Rodon, Jordi A.

المساهمون: HUS Comprehensive Cancer Center, Heikki Joensuu / Principal Investigator, Department of Oncology, Department of Biochemistry and Developmental Biology, Faculty of Medicine, University of Helsinki, Clinicum, Helsinki University Hospital Area

مصطلحات موضوعية: ODM-203, dose escalation study, phase I, solid tumours, FGFR and VEGFR inhibitor, ENDOTHELIAL GROWTH-FACTOR, PROGNOSTIC-SIGNIFICANCE, INHIBITOR, VEGF, 3122 Cancers

وصف الملف: application/pdf

العلاقة: The study was sponsored by Orion Corporation, Orion Pharma, Espoo, Finland.; Bono , P , Massard , C , Peltola , K J , Azaro , A , Italiano , A , Kristeleit , R S , Curigliano , G , Lassen , U , Arkenau , H-T , Hakulinen , P , Garratt , C , Ikonen , T , Mustonen , M V J & Rodon , J A 2020 , ' Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours ' , ESMO open , vol. 5 , no. 6 , 001081 . https://doi.org/10.1136/esmoopen-2020-001081Test; 98f21a47-b49b-43b7-b3d1-eb1e856f5e79; http://hdl.handle.net/10138/324382Test; 000597167800002

الإتاحة: http://hdl.handle.net/10138/324382Test

المؤلفون: Högbom, Lars, Abbas, Dalia, Armolaitis, Kęstutis, Bāders, Endijs, Futter, Martyn N., Jansons, Aris, Jõgiste, Kalev, Lazdins, Andis, Lukminė, Diana, Mustonen, Mika, Øistad, Knut, Poska, Anneli, Rautio, Pasi, Svensson, Johan, Vodde, Floor, Varnagirytė-Kabašinskienė, Iveta, Weslien, Jan, Wilhelmsson, Lars, Zute, Daiga

المصدر: Sustainability, Basel : MDPI , ST ALBAN-ANLAGE 66, BASEL, SWITZERLAND, CH-4052, 2021, 13, 10, 5643, p. 1-12 ; ISSN 2071-1050

مصطلحات موضوعية: United Nations Sustainable Development Goals, ecosystem services, forest, forestry, management practices, European Green Deal

العلاقة: http://lammc.lvb.lt/LAMMC:ELABAPDB102040378&prefLang=en_USTest

الإتاحة: https://doi.org/10.3390/su13105643Test
http://lammc.lvb.lt/LAMMC:ELABAPDB102040378&prefLang=en_USTest

المؤلفون: Peltola, Katriina J., Bono, Petri, Hugh Jones, Robert, Vjaters, Egils, Nykänen, Pirjo, Vuorela, Annamari, Oksala, Riikka, Pohjanjousi, Pasi, Mustonen , Mika V. J., Fizazi, Karim, Massard, Christophe

المساهمون: HUS Comprehensive Cancer Center, Department of Oncology, Heikki Joensuu / Principal Investigator, University Management

مصطلحات موضوعية: 3122 Cancers, 3126 Surgery, anesthesiology, intensive care, radiology, Androgen receptor, Castration-resistant prostate cancer, CYP17A1, ODM-204, Phase I clinical trial, ABIRATERONE, GENE, AMPLIFICATION, PROGRESSION

وصف الملف: application/pdf

العلاقة: Peltola , K J , Bono , P , Hugh Jones , R , Vjaters , E , Nykänen , P , Vuorela , A , Oksala , R , Pohjanjousi , P , Mustonen , M V J , Fizazi , K & Massard , C 2020 , ' ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer ' , European Urology Focus , vol. 6 , no. 1 , pp. 63-70 . https://doi.org/10.1016/j.euf.2018.08.022Test; RIS: urn:36741E580280AD791C9A6EE00A6CC7F0; 12b88df6-99aa-491c-b7d9-059e4a0fac3f; http://hdl.handle.net/10138/310589Test; 000505780500016

الإتاحة: http://hdl.handle.net/10138/310589Test

المؤلفون: Vahtola, Erik, Mustonen, Mika

المساهمون: Eero Mervaala / Ansvarig forskare, HUS Cancercentrum, Avdelningen för cancersjukdomar, HUS sjukvårdsområde

مصطلحات موضوعية: Drug Development, +trends, Antineoplastic Agents, Biomarkers, Tumor, 3122 Cancersjukdomar, 317 Farmaci

وصف الملف: application/pdf

العلاقة: Vahtola , E & Mustonen , M 2019 , ' Trender inom utvecklingen av onkologiska läkemedel ' , Finska Läkaresällskapets Handlingar , vol. 179 , nr. 1 , s. 68-73 . < https://www.fls.fi/Site/Data/884/Files/2019/Handlingar219_13.pdfTest >; RIS: urn:86CD4F3A88C8573EAB87BAE4FD94AE27; 1d99d1a1-d5cd-419d-aade-b5e76c74327e; http://hdl.handle.net/10138/318171Test

الإتاحة: http://hdl.handle.net/10138/318171Test

المؤلفون: Bono, Petri, Massard, Christophe, Peltola, Katriina J., Azaro, Analía, Italiano, Antoine, Kristeleit, Rebecca S., Curigliano, Giuseppe, Lassen, Ulrik, Arkenau, Hendrik Tobias, Hakulinen, Pasi, Garratt, Chris, Ikonen, Tarja, Mustonen, Mika V.J., Rodon, Jordi A.

المصدر: Bono , P , Massard , C , Peltola , K J , Azaro , A , Italiano , A , Kristeleit , R S , Curigliano , G , Lassen , U , Arkenau , H T , Hakulinen , P , Garratt , C , Ikonen , T , Mustonen , M V J & Rodon , J A 2020 , ' Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours ' , ESMO Open , vol. 5 , no. 6 , e001081 . ....

مصطلحات موضوعية: dose escalation study, FGFR and VEGFR inhibitor, ODM-203, phase I, solid tumours

وصف الملف: application/pdf

الإتاحة: https://doi.org/10.1136/esmoopen-2020-001081Test
https://curis.ku.dk/portal/da/publications/phase-iiia-openlabel-multicentre-study-to-evaluate-the-optimal-dosing-and-safety-of-odm203-in-patients-with-advanced-or-metastatic-solid-tumoursTest(7c12f293-11e9-4a2e-94ee-aba1d7c6b448).html
https://curis.ku.dk/ws/files/258769390/PIIS2059702920327654.pdfTest

المؤلفون: Huhtaniemi, Riikka, Oksala, Riikka, Knuuttila, Matias, Mehmood, Arfa, Aho, Eija, Laajala, Teemu D., Nicorici, Daniel, Aittokallio, Tero, Laiho, Asta, Elo, Laura, Ohlsson, Claes, Kallio, Pekka, Mäkelä, Sari, Mustonen, Mika V. J., Sipila, Petra, Poutanen, Matti

المساهمون: Institute for Molecular Medicine Finland, Tero Aittokallio / Principal Investigator, Bioinformatics

مصطلحات موضوعية: ANDROGEN RECEPTOR EXPRESSION, ABIRATERONE ACETATE, HORMONE AGONISTS, MECHANISMS, STEROIDOGENESIS, ENZALUTAMIDE, GENE, ANTIANDROGENS, BIOCONDUCTOR, TESTOSTERONE, 3111 Biomedicine

وصف الملف: application/pdf

العلاقة: Supported by the Academy of Finland, the Cancer Foundation of Finland, the Drug Research Doctoral Programme, the Finnish Cultural Foundation, the Sigrid Juselius Foundation, the Swedish government under the Agreement for Medical Education and Research, the Swedish Research Council, the University of Turku, and Orion Pharma of the Orion Corporation.; Huhtaniemi , R , Oksala , R , Knuuttila , M , Mehmood , A , Aho , E , Laajala , T D , Nicorici , D , Aittokallio , T , Laiho , A , Elo , L , Ohlsson , C , Kallio , P , Mäkelä , S , Mustonen , M V J , Sipila , P & Poutanen , M 2018 , ' Adrenals Contribute to Growth of Castration-Resistant VCaP Prostate Cancer Xenografts ' , The American Journal of Pathology , vol. 188 , no. 12 , pp. 2890-2901 . https://doi.org/10.1016/j.ajpath.2018.07.029Test; ORCID: /0000-0002-0886-9769/work/52695748; 85056748617; 60969d57-4a0e-45af-b03d-d010729a6002; http://hdl.handle.net/10138/307082Test; 000454187100015

الإتاحة: http://hdl.handle.net/10138/307082Test

المؤلفون: Shore, Neal D., Tammela, Teuvo L., Massard, Christophe, Bono, P., Aspegren, John, Mustonen, Mika, Fizazi, Karim

المساهمون: Heikki Joensuu / Principal Investigator, Clinicum, Department of Oncology, University of Helsinki, HUS Comprehensive Cancer Center

مصطلحات موضوعية: darolutamide, oxygenase inhibitor, prostate specific antigen, abdominal pain, adult, aged, antineoplastic activity, arthralgia, Article, backache, bone pain, cancer growth, castration resistant prostate cancer, clinical article, constipation, decreased appetite, dermatitis, diarrhea, dizziness, drug safety, drug tolerability, dysgeusia, dysuria, fatigue, femoral neck fracture, follow up, gynecomastia, headache, hematuria, hot flush

وصف الملف: application/pdf

العلاقة: Shore , N D , Tammela , T L , Massard , C , Bono , P , Aspegren , J , Mustonen , M & Fizazi , K 2018 , ' Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naïve and CYP17 Inhibitor-naïve Patients : Follow-up from the ARADES and ARAFOR Trials ' , European Urology Focus , vol. 4 , no. 4 , pp. 547-553 . https://doi.org/10.1016/j.euf.2017.01.015Test; Bibtex: urn:fb7a2e7bc047c3263cdc852c24e10e55; 85012908637; 88992e7d-9273-419c-b143-54e559fe7875; http://hdl.handle.net/10138/299672Test; 000486146500017

الإتاحة: http://hdl.handle.net/10138/299672Test